We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BD Launches Liverty TIPS Stent Graft to Expand U.S. Treatment
Read MoreHide Full Article
Key Takeaways
BDX launches Liverty TIPS Stent Graft in the United States to support personalized portal hypertension care.
Liverty offers adjustable 6-10 mm diameters, longer stent lengths and greater deployment control.
BD's Liverty launch is backed by ARCH study data from 177 patients and clinical experience in Europe.
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the U.S. commercial launch of the BD Liverty TIPS Stent Graft, a next-generation transjugular intrahepatic portosystemic shunt (TIPS) system designed to support more personalized treatment for patients with portal hypertension. The system provides physicians with greater flexibility, deployment accuracy and control to tailor procedures based on individual patient anatomy, disease progression and clinical goals.
Per management, the Liverty TIPS Stent Graft was developed to give physicians greater flexibility during TIPS procedures. Its extended stent lengths and adjustable diameter options are designed to help clinicians make real-time treatment decisions based on individual patient needs.
BDX Stock Trend Following the News
Year to date, the stock has gained 2% compared with the industry’s 13% growth and the S&P 500’s 9.3% rise.
The U.S. launch of Liverty could strengthen BD's position in the interventional vascular market by expanding its range of specialized treatment solutions. Offering a more adaptable TIPS platform may help BD attract additional physician interest and support product adoption across hospitals and interventional care centers. The launch also provides another opportunity for the company to leverage its clinical expertise and broaden its presence in specialized vascular procedures.
BDX currently has a market capitalization of $54.52 billion.
Image Source: Zacks Investment Research
More on the Liverty TIPS Stent Graft
Portal hypertension occurs when blood pressure increases in the portal vein system, potentially leading to serious complications such as internal bleeding and fluid accumulation in the abdomen. TIPS is a minimally invasive procedure that creates a new pathway for blood flow through the liver to relieve this pressure. It is commonly used to manage complications such as variceal bleeding and refractory ascites.
The Liverty TIPS Stent Graft is designed to accommodate varying patient requirements through an expandable diameter ranging from 6 to 10 millimeters and covered stent lengths of 4 to 10 centimeters, the longest commercially available. Its fully sheathed, tri-axial delivery system is intended to provide deployment control and accuracy. Radiopaque markers support visualization and placement under fluoroscopy, while the delivery system enables sheathless tracking through the liver parenchyma.
The U.S. launch is supported by six-month interim results from the prospective, multicenter ARCH clinical study, which enrolled 177 patients. The study is the first and only IDE study to provide clinical data on small-diameter (6-7 mm) TIPS. The system also enters the U.S. market with established clinical and physician experience in Europe.
With the commercial introduction of Liverty, BD continues to expand its interventional portfolio and provide physicians with additional options for managing complications associated with portal hypertension.
Industry Prospects Favoring the Market
According to Future Market Insights, the global portal hypertension management market is estimated to be valued at $3.5 billion in 2026 and is expected to witness a CAGR of 4.8% through 2036.
Factors such as the rising prevalence of chronic liver diseases and cirrhosis, increasing demand for treatments for variceal bleeding and other complications, growing adoption of minimally invasive procedures like TIPS and expanding interventional radiology capabilities at hepatology centers are expected to drive market growth.
Other News
BD recently advanced its pharmacy automation portfolio in the United States with the deployment of BD Vmax 160, its next-generation pharmacy automation robot at Fairview Health Services. The technology is designed to help high-volume centralized outpatient pharmacies manage the growing complexity of specialty and refrigerated medications while increasing fulfillment capacity and improving medication access.
Some other top-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Intuitive Surgical (ISRG - Free Report) and Globus Medical (GMED - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
View the Zacks #1 Rank List
Image: Bigstock
BD Launches Liverty TIPS Stent Graft to Expand U.S. Treatment
Key Takeaways
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, recently announced the U.S. commercial launch of the BD Liverty TIPS Stent Graft, a next-generation transjugular intrahepatic portosystemic shunt (TIPS) system designed to support more personalized treatment for patients with portal hypertension. The system provides physicians with greater flexibility, deployment accuracy and control to tailor procedures based on individual patient anatomy, disease progression and clinical goals.
Per management, the Liverty TIPS Stent Graft was developed to give physicians greater flexibility during TIPS procedures. Its extended stent lengths and adjustable diameter options are designed to help clinicians make real-time treatment decisions based on individual patient needs.
BDX Stock Trend Following the News
Year to date, the stock has gained 2% compared with the industry’s 13% growth and the S&P 500’s 9.3% rise.
The U.S. launch of Liverty could strengthen BD's position in the interventional vascular market by expanding its range of specialized treatment solutions. Offering a more adaptable TIPS platform may help BD attract additional physician interest and support product adoption across hospitals and interventional care centers. The launch also provides another opportunity for the company to leverage its clinical expertise and broaden its presence in specialized vascular procedures.
BDX currently has a market capitalization of $54.52 billion.
Image Source: Zacks Investment Research
More on the Liverty TIPS Stent Graft
Portal hypertension occurs when blood pressure increases in the portal vein system, potentially leading to serious complications such as internal bleeding and fluid accumulation in the abdomen. TIPS is a minimally invasive procedure that creates a new pathway for blood flow through the liver to relieve this pressure. It is commonly used to manage complications such as variceal bleeding and refractory ascites.
The Liverty TIPS Stent Graft is designed to accommodate varying patient requirements through an expandable diameter ranging from 6 to 10 millimeters and covered stent lengths of 4 to 10 centimeters, the longest commercially available. Its fully sheathed, tri-axial delivery system is intended to provide deployment control and accuracy. Radiopaque markers support visualization and placement under fluoroscopy, while the delivery system enables sheathless tracking through the liver parenchyma.
The U.S. launch is supported by six-month interim results from the prospective, multicenter ARCH clinical study, which enrolled 177 patients. The study is the first and only IDE study to provide clinical data on small-diameter (6-7 mm) TIPS. The system also enters the U.S. market with established clinical and physician experience in Europe.
With the commercial introduction of Liverty, BD continues to expand its interventional portfolio and provide physicians with additional options for managing complications associated with portal hypertension.
Industry Prospects Favoring the Market
According to Future Market Insights, the global portal hypertension management market is estimated to be valued at $3.5 billion in 2026 and is expected to witness a CAGR of 4.8% through 2036.
Factors such as the rising prevalence of chronic liver diseases and cirrhosis, increasing demand for treatments for variceal bleeding and other complications, growing adoption of minimally invasive procedures like TIPS and expanding interventional radiology capabilities at hepatology centers are expected to drive market growth.
Other News
BD recently advanced its pharmacy automation portfolio in the United States with the deployment of BD Vmax 160, its next-generation pharmacy automation robot at Fairview Health Services. The technology is designed to help high-volume centralized outpatient pharmacies manage the growing complexity of specialty and refrigerated medications while increasing fulfillment capacity and improving medication access.
Becton, Dickinson and Company Price
Becton, Dickinson and Company price | Becton, Dickinson and Company Quote
BDX’s Zacks Rank & Other Key Picks
Currently, BDX carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Intuitive Surgical (ISRG - Free Report) and Globus Medical (GMED - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Intuitive Surgical, currently carrying a Zacks Rank #2, reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.